EA030741B1 - Адъювантное соединение - Google Patents

Адъювантное соединение Download PDF

Info

Publication number
EA030741B1
EA030741B1 EA201490709A EA201490709A EA030741B1 EA 030741 B1 EA030741 B1 EA 030741B1 EA 201490709 A EA201490709 A EA 201490709A EA 201490709 A EA201490709 A EA 201490709A EA 030741 B1 EA030741 B1 EA 030741B1
Authority
EA
Eurasian Patent Office
Prior art keywords
leu
ser
lys
antigen
glu
Prior art date
Application number
EA201490709A
Other languages
English (en)
Russian (ru)
Other versions
EA201490709A1 (ru
Inventor
Фердинанд Антониус Осендорп
Корнелис Йоханнес Мария Мелиф
Селина Кан
Дмитрий Викторович Филиппов
Гейсберт Ари Ван Дер Марел
Original Assignee
АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В. filed Critical АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В.
Publication of EA201490709A1 publication Critical patent/EA201490709A1/ru
Publication of EA030741B1 publication Critical patent/EA030741B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
EA201490709A 2011-10-05 2012-10-04 Адъювантное соединение EA030741B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543510P 2011-10-05 2011-10-05
NL2007536A NL2007536C2 (en) 2011-10-05 2011-10-05 Adjuvant compound.
US201261615566P 2012-03-26 2012-03-26
PCT/NL2012/050694 WO2013051936A1 (en) 2011-10-05 2012-10-04 Adjuvant compound

Publications (2)

Publication Number Publication Date
EA201490709A1 EA201490709A1 (ru) 2014-09-30
EA030741B1 true EA030741B1 (ru) 2018-09-28

Family

ID=48043964

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490709A EA030741B1 (ru) 2011-10-05 2012-10-04 Адъювантное соединение

Country Status (16)

Country Link
US (2) US9314521B2 (forum.php)
EP (1) EP2763697B9 (forum.php)
JP (1) JP6099210B2 (forum.php)
KR (1) KR102053699B1 (forum.php)
CN (1) CN104244976B (forum.php)
AU (1) AU2012319265B2 (forum.php)
BR (1) BR112014008214B1 (forum.php)
CA (1) CA2886631C (forum.php)
EA (1) EA030741B1 (forum.php)
ES (1) ES2952644T3 (forum.php)
IL (1) IL231951B (forum.php)
IN (1) IN2014DN03325A (forum.php)
MX (1) MX356028B (forum.php)
NL (1) NL2007536C2 (forum.php)
SG (1) SG11201401291XA (forum.php)
WO (1) WO2013051936A1 (forum.php)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1219477A1 (zh) 2013-03-21 2017-04-07 Sanofi-Aventis Deutschland Gmbh 合成含有乙内酰脲的肽产物
HUE033371T2 (en) 2013-03-21 2017-11-28 Sanofi Aventis Deutschland Process for the preparation of peptide products containing a ring imide
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
US10376576B2 (en) 2014-06-02 2019-08-13 Isa Pharmaceuticals B.V. Synthetic long peptides (SLP) for therapeutic vaccination against hepatitis B virus infection
US10253062B2 (en) 2014-12-23 2019-04-09 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
HK1255541A1 (zh) 2015-12-11 2019-08-23 Immatics Biotechnologies Gmbh 用於多种癌症免疫治疗的新型肽和肽组合物
SG11201807036QA (en) 2016-02-26 2018-09-27 Auckland Uniservices Ltd Amino acid and peptide conjugates and conjugation process
MY201964A (en) 2016-06-20 2024-03-27 Isa Pharmaceuticals B V Formulation of a peptide vaccine
AU2017292934B9 (en) 2016-07-07 2024-08-29 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
CA3057715A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
AU2020397499A1 (en) 2019-12-07 2022-06-16 Erasmus University Medical Center Rotterdam Treatment of diseases related to hepatitis B virus
US20230087422A1 (en) 2020-02-07 2023-03-23 Isa Pharmaceuticals B.V. Treatment of hpv-related diseases
US20230143215A1 (en) 2020-04-23 2023-05-11 Isa Pharmaceuticals B.V. Immunization against sars-cov-related diseases
KR20240029765A (ko) 2021-07-12 2024-03-06 아이에스에이 파마슈티컬즈 비.브이. 복잡한 혼합물에서의 개선된 물질 정량화
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
EP4601685A1 (en) 2022-10-13 2025-08-20 Isabella Pharma B.V. Modified long peptides suitable for use in immunisation
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025008085A1 (en) 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431327A1 (de) * 1989-11-10 1991-06-12 Hoechst Aktiengesellschaft Synthetische Vakzine zur spezifischen Induktion zytotoxischer T-Lymphozyten

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67769T1 (de) * 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
CN1367829A (zh) 1999-06-30 2002-09-04 科里克萨有限公司 用于肺癌治疗和诊断的组合物和方法
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NL1012739C2 (nl) 1999-07-29 2001-01-30 Maasland Nv Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer.
US7202034B2 (en) 2000-12-08 2007-04-10 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
MXNL04000056A (es) 2004-06-30 2006-01-11 Mario Alberto Aguilera Rico Sistema de construccion terra acero.
EP2061507A4 (en) * 2006-08-14 2010-08-18 Thymon Llc COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF SEVERAL HIV-1 STRAINS AND SUB-TYPES
EP2125005B1 (en) 2007-03-26 2015-04-08 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
AU2008257791B2 (en) 2007-05-31 2013-03-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
EP3584251A3 (en) 2007-05-31 2020-01-29 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
EA031379B1 (ru) * 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431327A1 (de) * 1989-11-10 1991-06-12 Hoechst Aktiengesellschaft Synthetische Vakzine zur spezifischen Induktion zytotoxischer T-Lymphozyten

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOYLE PETER M; TOTH ISTVAN: "Self-adjuvanting lipopeptide vaccines.", CURRENT MEDICINAL CHEMISTRY, BENTHAM, NL, vol. 15, no. 5, 1 January 2008 (2008-01-01), NL, pages 506 - 516, XP009104575, ISSN: 0929-8673, DOI: 10.2174/092986708783503249 *
TSUNEAKI HIDA, KOZO HAYASHI, KOICHI YUKISHIGE, SEIICHI TANIDA, NORIAKI KAWAMURA, SETSUO HARADA: "Synthesis and Biological Activities of TAN-1511 Analogues.", THE JOURNAL OF ANTIBIOTICS, vol. 48, no. 7, 1 January 1995 (1995-01-01), pages 589 - 603, XP055023889, ISSN: 00218820, DOI: 10.7164/antibiotics.48.589 *

Also Published As

Publication number Publication date
CN104244976B (zh) 2017-05-31
NL2007536C2 (en) 2013-04-08
IL231951A0 (en) 2014-05-28
WO2013051936A9 (en) 2013-09-12
NZ623869A (en) 2015-11-27
KR20140093673A (ko) 2014-07-28
EP2763697B8 (en) 2023-07-12
AU2012319265A1 (en) 2014-05-22
BR112014008214B1 (pt) 2022-07-05
ES2952644T3 (es) 2023-11-02
IN2014DN03325A (forum.php) 2015-06-26
CN104244976A (zh) 2014-12-24
EA201490709A1 (ru) 2014-09-30
US20150104473A1 (en) 2015-04-16
SG11201401291XA (en) 2014-05-29
WO2013051936A1 (en) 2013-04-11
EP2763697B9 (en) 2023-10-04
MX356028B (es) 2018-05-09
KR102053699B1 (ko) 2019-12-09
AU2012319265B2 (en) 2016-10-13
IL231951B (en) 2019-08-29
EP2763697B1 (en) 2023-06-07
JP2014530808A (ja) 2014-11-20
CA2886631A1 (en) 2013-04-11
JP6099210B2 (ja) 2017-03-22
EP2763697C0 (en) 2023-06-07
US20160250325A1 (en) 2016-09-01
BR112014008214A2 (pt) 2017-06-13
US9770506B2 (en) 2017-09-26
CA2886631C (en) 2019-06-11
EP2763697A1 (en) 2014-08-13
US9314521B2 (en) 2016-04-19
MX2014004114A (es) 2014-10-17

Similar Documents

Publication Publication Date Title
US9770506B2 (en) Adjuvant compound
JP7190528B2 (ja) 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びtlrペプチドアゴニストを含む新規複合体
JP7181880B2 (ja) 免疫療法のためのコア/シェル構造プラットホーム
CN104736553B (zh) 细胞穿透肽
JP5230579B2 (ja) 癌抑制遺伝子wt1の産物に基づく癌抗原
ES2676630T3 (es) Control inmunogénico de tumores y células tumorales
RU2011125306A (ru) Праймирование иммунного ответа
US12016918B2 (en) Peptide-containing adjuvant compounds having peg spacers
JP2023507347A (ja) ネオエピトープをコードするコンストラクトを使用する核酸ワクチン接種
CN113906046A (zh) 具有包含经修饰半胱氨酸的氧化还原酶基序的免疫原性肽
NZ623869B2 (en) Improved pam3cys-like lipopeptide adjuvant compound

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ